

**BIOACTIVE CONSTITUENTS AND ANTI-
INFLAMMATORY EFFECT OF AGARWOOD LEAF
EXTRACT AND ITS NANO-ENCAPSULATED AS
HALAL THERAPEUTIC ALTERNATIVE**

BY

MANAR ABDULLAH EISSA

A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy in Halal Industry

International Institute for Halal Research and Training

International Islamic University Malaysia

SEPTEMBER 2021

ABSTRACT

The serious adverse effects associated with the prolonged use of synthetic anti-inflammatory medications have raised concerns in the pharmaceutical field. In response, the pharmaceutical industry has begun to embrace the halal built-in approach to meet the desired unified attributes of safety and high quality. This work is focused on *Aquilaria malaccensis* (Family Thymelaeaceae), an agarwood-producing tree geographically distributed in Indomalesian rainforests. Different parts of the tree have been traditionally used to treat several medical disorders including inflammatory-related conditions. However, the scientific evaluation of the anti-inflammatory related traditional claims of this plant has been very scarce. In this study, *A. malaccensis* ethanolic leaf extract (ALEX-M) is subjected to characterization via phytochemical screening, FTIR, GC-MS and LC-MS. The extract was also subjected to isolation of bioactive compounds with anti-inflammatory potential using column chromatography. The structures of the isolated compounds were elucidated using HREIMS, IR, UV, 1D and 2D NMR spectroscopy. Polymeric nanocapsules were fabricated using water-in-oil-in-water (w/o/w) emulsion method using Tragacanth gum as a natural and Halal polymer to encapsulate the extract. The toxicity and anti-inflammatory activity of the free extract (ALEX-M) and nanoencapsulated extract (ALEX-M-PNCs) were assessed in-vitro on RAW264.7 macrophages and in Zebrafish embryos. The findings revealed that a total of 58 compounds were tentatively identified in the extract using LC-Q-TOF-MS, some of which have been previously reported to exhibit anti-inflammatory activity. The dichloromethane and ethyl acetate fractions yielded eight compounds including one terpenoid, four flavonoids and three benzophenones. DCM-C2, DCM-C4, EA-C5 and EA-C7 demonstrated the highest inhibition of NO production in LPS-stimulated RAW 264.7 macrophages with EC_{50} =27.75, 35.25, 16.65 and 27.78 $\mu\text{g/mL}$, respectively. The extract-loaded nanocapsules (ALEX-M-PNCs) were spherical in shape with desirable size (167.13 ± 1.24 nm) and polydispersity index (0.29 ± 0.01) and demonstrated relatively high encapsulation efficiency (87.36 ± 1.81 %). ALEX-M demonstrated high viability on RAW 264.7 cells and towards zebrafish embryos at high concentrations in contrast to nanocapsules that showed relatively higher cytotoxicity. ALEX-M and ALEX-M-PNCs demonstrated ability to reduce NO production in LPS-stimulated macrophages in a dose-dependent manner with EC_{50} values of 164.790 ± 6.318 $\mu\text{g/mL}$ and 5.50 ± 0.31 $\mu\text{g/mL}$, respectively. A significant reduction in the amount of NO was also observed with ALEX-M and ALEX-M-PNCs in LPS-treated zebrafish embryos with EC_{50} values of 43.09 ± 7.67 $\mu\text{g/mL}$ and 11.92 ± 2.61 $\mu\text{g/mL}$, respectively. The results confirmed the traditional use of *A. malaccensis* in the management of inflammation and supports its use as a safe and Halal therapeutic alternative. In addition, nano-encapsulation of the extract potentiated its anti-inflammatory effect. Further in-depth research can be conducted to elucidate the mechanisms underlying the anti-inflammatory effect of the extract.

خلاصة البحث

ان الاستخدام طويل الأمد للعقاقير الطبية المضادة للالتهابات وما يترتب عليها من أعراض جانبية قد أثار الكثير من المخاوف مؤخرا. ومن هنا، بدأت الصناعات الدوائية في تبني منهج الحلال لتحقيق المعايير القياسية للسلامة والجودة. وفي هذا البحث، تم اختيار شجرة *Aquilaria malaccensis*، من عائلة Thymelaeaceae، وهي احدى أشجار العود المتركة جغرافيا في الغابات المطيرة الاندوماليزية، حيث سبق استخدام أجزاء مختلفة من الشجرة في العلاج التقليدي للعديد من المشاكل الصحية بما في ذلك علاج الالتهابات، إلا أن الاثبات العلمي لهذا الاستخدام التقليدي للنبات كمضاد للالتهابات لا يزال مطلوبا. في هذه الدراسة، يخضع المستخلص الإيثانولي للنبات (ALEX-M) إلى دراسة شاملة للخصائص باستخدام الفحص الكيميائي ومطياف متحول فورييه في مجال الضوء تحت الأحمر (FTIR) ومطياف الكتلة للكروماتوغرافيا الغازية (GC-MS) و مطياف الكتلة للكروماتوغرافيا السائلة (LC-MS) بالإضافة إلى فصل المركبات النشطة بيولوجيا ذات الفاعلية المضادة للالتهابات باستخدام عمود الكروماتوغرافيا (CC) ثم توضيح هياكلها باستخدام طرق التحليل المختلفة مثل HREIMS و IR و UV و NMR أحادي وثنائي الأبعاد. ومن خلال استخدام طريقة المستقلب المركب (w / o / w) واختيار الصمغ Tragacanth كبوليمر طبيعي وحلال، تم تصنيع الكبسولات النانوية البوليمرية لتغليف المستخلص في المعمل (in-vitro)، تم اجراء اختبار السمية الخلوية والنشاط المضاد للالتهابات للمستخلص الحر (ALEX-M) أو المستخلص داخل الحبوب النانوية (ALEX-M-PNCs) في خلايا RAW 264.7 وباستخدام أجنة سمك الزبيرا. أظهرت النتائج أنه عن طريق استخدام مطياف الكتلة للكروماتوغرافيا السائلة (LC-Q-TOF-MS)، تم الكشف عن وجود ما يعادل ٥٨ مركبا بصورة مبدئية في المستخلص، وقد تم إثبات فعالية بعض هذه المركبات في أبحاث سابقة كمركبات مضادة للالتهابات. و تم استخلاص ثمانية مركبات من مستخلص المذيبات العضوية - مثل ثنائي كلورو ميثان وأسيات الإيثيل - تشمل تربينويد واحد وأربعة من مركبات الفلافونويد وثلاثة من بنزوفينونات. واتضح أن المركبات (DCM-C2, DCM-C4, EA-C5, EA-C7) أثبتت فعالية في تثبيط إنتاج أكسيد النيتريت (NO) في الخلايا RAW 264.7 المحفزة ب LPS وكان التركيز الذي تثبط ٥٠٪ (EC_{50}) من أكسيد النيتريت (NO) لهذه المركبات يعادل 27.75 و 35.25 و 16.65 و 27.78 ميكروغرام / مل ، على التوالي. كما وجد أن الكبسولات النانوية المحملة بالمستخلص كروية الشكل وذات حجم نانوي (167.13 ± 1.24 nm) بمعامل التشتت المتعدد polydispersity (0.29 ± 0.01) ، كما أظهرت كفاءة تغليف عالية نسبيا (1.81 ± 87.36 ٪). أظهرت الكبسولات النانوية ALEX-M-PNCs سمية خلوية أعلى نسبيا من ALEX-M في خلايا RAW 264.7 واتجاه أجنة سمك الزبيرا. وكذلك أظهر كلا من المستخلص الحر والمستخلص داخل الحبوب النانوية القدرة على تقليل إنتاج أكسيد النيتريت (NO) المحفزة عن طريق LPS في خلايا RAW 264.7 وتزداد طرديا بزيادة الجرعة. و بحساب قيمة التركيز الذي تثبط ٥٠٪ من أكسيد النيتريت (EC_{50}) المستخلص الحر والمستخلص داخل الحبوب النانوية ، كانت الجرعات 6.318 ± 164.790 ميكروغرام/مل و 0.31 ± 5.50 ميكروغرام/مل ، على التوالي. كما لوحظ أيضاً انخفاض كبير في كمية NO في أجنة سمك الزبيرا بالمعالجة بالمستخلص الحر والمستخلص داخل الحبوب النانوية بعد تحفيزها بمركب LPS وبلغ التركيز الذي تثبط ٥٠٪ (EC_{50}) من أكسيد النيتريت 7.67 ± 43.09 ميكروغرام/مل و 2.61 ± 11.92 ميكروغرام / مل ، على التوالي. وخلصت نتائج البحث إلى دعم الاستخدام التقليدي لـ *Aquilaria malaccensis* في علاج الالتهابات كبديل علاجي آمن وحلال. بالإضافة إلى ذلك ، فإن تحميل المستخلص في حبوب نانوية يعزز من تأثيره المضاد للالتهابات كما ظهر في خلايا RAW 264.7 وأجنة سمك الزبيرا. ويمكن إجراء مزيد من البحوث المتعمقة لتوضيح الآليات الكامنة وراء التأثير المضاد للالتهابات للمستخلص.

APPROVAL PAGE

The thesis of Manar Abdullah Eissa has been approved by the following:

Prof. Dr. Yumi Zuhanis Has-Yun Bt. Hashim
Supervisor

Prof. Hamzah Mohd. Salleh
Co-Supervisor

Asst. Prof. Dr. Yusilawati Binti Ahmad Nor
Co-Supervisor

Assoc. Prof. Dr. Muhammad Lokman Bin Md. Isa
Co-Supervisor

Assoc. Prof. Dr. Saripah Salbiah Syed Abdul Azziz
Field Supervisor

Prof. Dr. Irwandi Jaswir
Internal Examiner

Assoc. Prof. Dr. Ahmad Rohi Bin Ghazali
External Examiner

Assoc. Prof. Dr. Hazrulrizawati bt Abd Hamid
External Examiner

Assoc. Prof. Dr. Radwan Jamal Elatrash
Chairman


DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Manar Abdullah Eissa

Signature

Date



**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**BIOACTIVE CONSTITUENTS AND ANTI-INFLAMMATORY
EFFECT OF AGARWOOD LEAF EXTRACT AND ITS NANO-
ENCAPSULATED AS HALAL THERAPEUTIC ALTERNATIVE**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2021 Manar Abdullah Eissa and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understood the IIUM Intellectual Property Right and Commercialisation policy.


Affirmed by Manar Abdullah Eissa

.....

Signature

.....

Date



I dedicate my dissertation to my family and my beloved husband. My achievements were made possible by their constant love and encouragement. Their immeasurable support has sustained me throughout my journey.

ACKNOWLEDGEMENTS

First and foremost, I am indebted to Allah Subhanahu Wa Taa'la for His eternal protection, mercies, blessings and guidance through the course of this work. This PhD thesis is the output of the support of several people to whom I am extremely grateful.

My ultimate gratitude and deepest appreciation goes to my family for being loving, encouraging, understanding, and for easing much of my stress.

My deepest gratefulness goes to my husband. His immense encouragement and admirable patience helped me overcome the hardships in my PhD. His wise and positive words gave me the strength and courage to continue. Thank you from the deep of my heart for helping me shape my future.

I will forever be thankful to my supervisor, Professor Yumi Zuhani, for her continuous support throughout this project. Many thanks also goes to Associate Professor, Dr. Saripah, my field supervisor for her tremendous efforts, and to Prof. Hamzah Salleh and Dr. Yusilawati for their follow up and valuable feedback.

I am also profoundly grateful for my co-authors, Dr. Hamza Nasir, Dr. Dina ElKersh and Dr. Noha Alaa.

An honorable mention goes to the British University in Egypt for opening their labs and providing all materials and facilities to me. I also acknowledge the financial support provided by the ministry of higher education in Malaysia under research grant FRGS/1/2019/WAB11/UIAM/02/4.

Once again, I glorify Allah Subhanahu Wa Taa'la for his endless blessings which enabled me to complete this work.

TABLE OF CONTENTS

Abstract.....	ii
Abstract in Arabic.....	iii
Approval Page	iv
Declaration.....	v
Copyright Page	vi
Dedication.....	vii
Acknowledgements	viii
List of Tables	xiv
List of Figures.....	xvi
List of Equations.....	xxi
List of Abbreviations	xxii
CHAPTER ONE: INTRODUCTION	1
1.1 Background of the Study	1
1.2 Problem Statement.....	6
1.3 Research Philosophy and Hypotheses	6
1.4 Research Objectives.....	7
1.5 Problem Scope.....	8
1.6 Significance of Study.....	9
1.7 Thesis Outline.....	10
1.8 Conclusion	11
CHAPTER TWO: LITERATURE REVIEW	12
2.1 Introduction.....	12
2.2 Inflammation.....	13
2.2.1 Definition.....	13
2.2.2 Pathophysiology	13
2.2.3 Inflammation as an Underlying Cause of Chronic Diseases ..	15
2.2.4 Conventional Treatment	15
2.2.5 Anti-Inflammatory Assays	16
2.2.5.1 In-vitro Anti-Inflammatory Assays	17
2.2.5.1.1 Inhibition of Albumin Denaturation	17
2.2.5.1.2 Inhibition of Nitric Oxide (NO) Levels	17
2.2.5.1.3 Anti-Lipoxygenase Assay.....	18
2.2.5.2 In-vivo Anti-Inflammatory Assays.....	19
2.3 Halal Alternatives	19
2.3.1 The Concept of “Halalan Toyyiban”	19
2.3.2 “Halalan Toyyiban” and Maqasid Al-Shariah.....	20
2.3.3 Halal Pharmaceuticals	20
2.4 Traditional Medicine	21
2.5 Extraction of Natural Products	21
2.6 Secondary Metabolites.....	22

2.7 The Genus Aquilaria.....	23
2.7.1 Phytochemicals Identified in Aquilaria Genus.....	24
2.7.2 Aquilaria Species as a Potential Source of Anti-Inflammatory Agents	44
2.8 Aquilaria Malaccensis	64
2.8.1 Traditional Used	65
2.8.2 Pharmacological Activity of Aquilaria Malaccensis.....	67
2.9 Nanotechnology.....	70
2.9.1 Types of Nanoparticles.....	71
2.9.2 Polymeric Nanoparticles as Drug-Delivery Systems	72
2.9.3 Nano-Encapsulation of Plant-based Products	75
2.9.4 Methods of Preparation	77
2.9.5 Tragacanth Gum Polymer.....	79
2.10 Zebrafish	82
2.10.1 Advantages and Disadvantages	82
2.10.2 Zebrafish Embryos as a Model for Screening Activity of Plant-Based Products.....	84
2.10.3 Zebrafish Embryos as a Model for Screening Toxicity of Plant-Based Products.....	86
2.10.4 Zebrafish Embryos as a Model in Nanotechnology Studies	87
2.11 Research Gap	89
2.12 Conclusion	89

CHAPTER THREE: MATERIALS AND METHODS 91

3.1 Introduction.....	91
3.2 Materials	92
3.2.1 Plant Material	92
3.2.2 Chemicals and Reagents.....	93
3.2.3 Cell Lines	94
3.2.4 Animals	94
3.2.4.1 Ethical Consideration	94
3.3 Methodology.....	95
3.3.1 Sample Preparation.....	95
3.3.2 Extraction	95
3.3.3 Characterization of the Leaf Extract.....	96
3.3.3.1 Preliminary Phytochemical Screening.....	96
3.3.3.2 GC-MS Analysis.....	97
3.3.3.3 Liquid Chromatography Quad Time of Flight Mass Spectrometry (LC-Q-TOF-MS)	97
3.3.4 Preparation of Cell Culture.....	99
3.3.4.1 Preparation of Complete Media.....	99
3.3.4.2 Culturing RAW 264.7 Macrophages	99
3.3.4.3 Sub-Culturing	99
3.3.4.4 Cell Counting and Viability.....	100
3.3.5 Sample Extraction and Fractionation	100
3.3.5.1 Chromatographic Separation of the Compounds.....	101
3.3.5.2 Thin Layer Chromatography (TLC)	102
3.3.5.3 Identification of Isolated Compounds	103

3.3.5.3.1 Ultra violet (UV) Spectroscopy	103
3.3.5.3.2 Liquid Chromatography Mass Spectrometry (LC-MS).....	103
3.3.5.3.3 Fourier Transform Infrared (FTIR) Spectroscopy	104
3.3.5.3.4 Nuclear Magnetic Resonance (NMR) Spectroscopy	104
3.3.6 Cytotoxicity Assays.....	104
3.3.6.1 WST-1 Toxicity Screening Assay	104
3.3.6.2 MTT Cytotoxicity Assay	105
3.3.7 Anti-Inflammatory Assays	106
3.3.7.1 Inhibition of Albumin Denaturation	106
3.3.7.2 Anti-Lipoxygenase Assay.....	107
3.3.7.3 Anti-Inflammatory Griess Assay.....	108
3.3.8 Fabrication of Nanocapsules	109
3.3.9 UV-Vis Spectroscopy.....	110
3.3.10 Characterization of Polymeric Nanocapsules.....	111
3.3.10.1 Measurement of Particle Size, Polydispersity Index (PDI) and Zeta Potential (ZP)	111
3.3.10.2 Morphological Analysis using Transmission Electron Microscope (TEM).....	111
3.3.10.3 Encapsulation Efficiency (EE)	112
3.3.10.4 Loading Capacity (LC).....	112
3.3.10.5 In-Vitro Drug Release	113
3.3.10.6 Thermogravimetric Analysis (TGA)	113
3.3.10.7 Fourier Transform Infrared (FTIR)	114
3.3.11 Stability Study	114
3.3.12 Zebrafish Embryo Toxicity Test (ZFET)	114
3.3.13 LPS-Induced Anti-Inflammatory Assay in Zebrafish Embryo	116
3.4 Statistical Analysis.....	117
3.5 Conclusion	117

**CHAPTER FOUR: RESULTS AND DISCUSSION:
CHARACTERIZATION OF AQUILARIA MALACCENSIS**

LEAF ETHANOLIC EXTRACT	118
4.1 Introduction.....	118
4.2 Extraction.....	118
4.3 Phytochemical Screening.....	120
4.4 GCMS	121
4.5 Fourier Transform Infrared Spectroscopy (FTIR).....	123
4.6 Liquid Chromatography Mass Spectrometry (LCMS).....	125
4.6.1 Phenolic Acids.....	127
4.6.2 Benzophenones.....	128
4.6.3 Flavonoids	131
4.6.3.1 Flavanols.....	132
4.6.3.2 Flavonols	133
4.6.3.3 Flavonones.....	135

4.6.3.4 Flavones.....	135
4.6.3.5 Isoflavones.....	139
4.6.3.6 Xanthones.....	139
4.6.3.7 Sterols.....	140
4.6.3.8 Terpenoids.....	142
4.6.3.9 Coumarins.....	143
4.6.3.10 Lignans.....	144
4.6.3.11 Fatty Acids.....	144
4.6.3.12 Tocopherols.....	145
4.7 Preliminary Screening Assays.....	151
4.7.1 Toxicity Screening Assay.....	151
4.7.2 Anti-Inflammatory Screening Assay.....	151
4.7.2.1 Protein Denaturation Assay.....	151
4.7.2.2 Anti-Lipoxygenase Assay.....	154
4.7.2.3 Inhibition of NO Production in LPS-Stimulated RAW 264.7 Macrophages.....	155
4.8 Conclusion.....	157

CHAPTER FIVE: RESULTS AND DISCUSSION: ISOLATION AND STRUCTURAL ELUCIDATION OF BIOACTIVE

COMPOUNDS.....	158
5.1 Introduction.....	158
5.2 Bioguided Fractionation.....	158
5.3 Chromatographic Separation of Compounds from DCM Fraction	161
5.4 Structural Elucidation of the Isolated Compounds from Dichloromethane Fraction.....	163
5.4.1 Compound DCM-C1: Epifriedelanol.....	164
5.4.2 Compound DCM-C2: 5-Hydroxy-7,4'-Dimethoxyflavone .	174
5.4.3 Compound DCM-C3: Luteolin-7,3',4'-Trimethyl Ether.....	187
5.4.4 Compound DCM-C4: 5,3'-dihydroxy-7,4'- dimethoxyflavone (Luteolin 7,4'-dimethyl ether).....	199
5.5 Chromatographic Separation of Compounds from Ethyl Acetate Crude Extract.....	211
5.6 Structural Elucidation of the Isolated Compounds from Ethyl Acetate Crude Extract.....	213
5.6.1 Compound EA-C5: 5,7-dihydroxy-4'-Methoxyflavone (Acacetin).....	213
5.6.2 Compound EA-C6: Aquilarinenside E.....	225
5.6.3 Compound EA-C7: Iriflophenone 2- O- α -L- rhamnopyranoside.....	234
5.6.4 Compound EA-C8: Iriflophenone 3-C- β -glucoside.....	244
5.6.5 The Anti-Inflammatory Activity of Crude Extract and Pure Compounds.....	256
5.7 Conclusion.....	268

CHAPTER SIX: RESULTS AND DISCUSSION: FABRICATION AND CHARACTERIZATION OF EXTRACT-LOADED POLYMERIC NANOCAPSULES AND EVALUATION OF THE

ANTI-INFLAMMATORY EFFECT OF FREE AND NANO-ENCAPSULATED EXTRACT IN-VITRO	269
6.1 Introduction.....	269
6.2 Fabrication of Nanocapsules.....	269
6.3 UV-Vis Spectroscopy.....	274
6.4 Characterization.....	275
6.4.1 Size, Polydispersity Index (PDI) and Zetapotential.....	275
6.4.2 Morphology.....	278
6.4.3 Encapsulation Efficiency (EE) and Loading Capacity	279
6.4.4 Loading Capacity (LC)	281
6.4.5 Release	281
6.4.6 Thermogravimetric Analysis.....	283
6.4.7 FTIR.....	285
6.5 Stability.....	287
6.6 Anti-Inflammatory Activity of the Free Extract and Extract-Loaded Nanocapsules In-Vitro.....	288
6.6.1 Determination of NonToxic Concentrations of Free and Nano-Encapsulated Extract using RAW 264.7 Cell Line.....	288
6.6.2 Anti-Inflammatory Griess Assay	291
6.7 Conclusion	297

CHAPTER SEVEN: RESULTS AND DISCUSSION: EVALUATION OF THE TOXICITY AND ANTI-INFLAMMATORY ACTIVITY OF THE FREE AND NANO-ENCAPSULATED AQUILARIA MALACCENSIS LEAF EXTRACT IN-VIVO.....	299
7.1 Introduction.....	299
7.2 Immersion Delivery of Samples to Zebrafish Embryos	299
7.3 Zebrafish Embryo Toxicity Test (ZFET)	300
7.3.1 Lethal Effects of ALEX-M, ALEX-M-PNCs and B-PNCs on Embryonic Development of Zebrafish.....	302
7.3.2 Spontaneous Movement of Zebrafish Embryo	306
7.3.3 Body Malformations in Zebrafish Embryos	308
7.3.4 Hatching Rate.....	309
7.3.5 Heart Rate	312
7.4 Anti-Inflammatory Activity of the Free Extract and Extract-Loaded Polymeric Nanocapsules In-Vivo	313
7.4.1 Preliminary Toxicity Assay	314
7.4.2 Anti-Inflammatory Assay	315
7.5 Conclusion	321

CHAPTER EIGHT: CONCLUSION AND RECOMMENDATIONS.....	322
8.1 Introduction.....	322
8.2 Conclusion.....	324
8.3 Recommendations for Future Work.....	325

REFERENCES.....	328
APPENDIX A	369
APPENDIX B	399

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	Phytochemical constituents isolated from different parts of <i>Aquilaria</i> species.	25
2.2	In-vitro anti-inflammatory studies on <i>Aquilaria</i> species	46
2.3	In-vivo anti-inflammatory studies on <i>Aquilaria</i> species	55
3.1	Phytochemical preliminary tests	96
4.1	Summary of the phytochemical screening of the ethanolic extract of <i>A. malaccensis</i> leaves	121
4.2	Chemical constituents identified in ethanolic extract of <i>A. malaccensis</i> leaves by GC-MS.	123
4.3	Metabolites identified in <i>A. malaccensis</i> leaf ethanolic extract via LC-Q-TOF-MS in negative (N) and positive (P) ionization modes.	147
4.4	Results of inhibition of albumin denaturation in-vitro by <i>A. malaccensis</i> leaf extract	153
4.5	Percentage of inhibition of lipoxygenase enzyme by <i>A. malaccensis</i> leaf extract	154
4.6	Percentage of inhibition of NO production in LPS-stimulated RAW 264.7 cells by <i>A. malaccensis</i> leaf extract and Ibuprofen	157
5.1	The fractions of the ethanolic extract of <i>A. malaccensis</i> leaves	158
5.2	Percentage of inhibition of lipoxygenase enzyme at a dose of 200µg/ml	159
5.3	Percentage of inhibition of NO production in LPS-stimulated RAW 264.7 cells at a dose of 200µg/ml	159
5.4	TLC of dichloromethane fraction of <i>A. malaccensis</i> leaf extract	160
5.5	TLC of ethyl acetate fraction of <i>A. malaccensis</i> leaf extract	160
5.6	¹ H NMR (500 MHz, CDCl ₃), ¹³ C NMR (125 MHz, CDCl ₃) and ¹ H- ¹ H COSY spectra data of compound DCM-C1 and epifriedelanol	169
5.7	¹ H NMR (CDCl ₃ , 500 MHz), ¹³ C NMR (CDCl ₃ , 125 MHz), ¹ H- ¹ H COSY, HMQC and HMBC spectral data of compound DCM-C2 and 5-Hydroxy-7,4'-dimethoxyflavone	180
5.8	¹ H NMR (CDCl ₃ , 500 MHz), ¹³ C NMR (CDCl ₃ , 125 MHz), ¹ H- ¹ H COSY, HMQC and HMBC spectral data of compound DCM-C3 and Luteolin-7,3',4'-trimethyl ether	192
5.9	¹ H NMR (CDCl ₃ , 500 MHz), ¹³ C NMR, (CDCl ₃ , 125 MHz), ¹ H- ¹ H COSY, HMQC and HMBC spectral data of	204

	compound DCM-C4 and 5,3'-Dihydroxy-7,4'- dimethoxyflavone	
5.10	¹ H NMR (DMSO-d ₆ , 500 MHz), ¹³ C NMR (DMSO-d ₆ , 125 MHz), ¹ H- ¹ H COSY, HMQC, HMBC spectral data of compound EA-C5 and 5,7-dihydroxy-4'- methoxyflavone (Acacetin)	218
5.11	¹ H NMR (CD ₃ OD, 500 MHz), ¹³ C NMR (CD ₃ OD, 125 MHz) and ¹ H- ¹ H COSY spectral data of compound EA- C6 and Aquilarinenside E	229
5.12	¹ H NMR (CD ₃ OD, 500 MHz), ¹³ C NMR (CD ₃ OD, 125 MHz) and ¹ H- ¹ H COSY spectral data of compound EA- C7 and Iriflophenone 2- <i>O</i> - α -L-rhamnopyranoside	239
5.13	¹ H NMR (CD ₃ OD, 500 MHz), ¹³ C NMR (Methanol, 125 MHz), ¹ H- ¹ H COSY, HMQC and HMBC spectral data of compound EA-C8 and iriflophenone 3- <i>C</i> - β -glucoside	249
5.14	The viability percentage (%) of the tested samples at different concentrations	257
5.15	The EC ₅₀ of the extract and the isolated compounds at different concentrations	266
6.1	Particle size and PDI of B-PNCs by DLS technique in different formulations	272
6.2	Mean diameter and PdI of ALEX-M-PNCs dispersions with different amounts of ALEX-M	280
6.3	The mean diameter, PDI and EE% of ALEX-M-PNCs dispersion at 4°C for evaluation of stability	288
6.4	Cytotoxicity and Anti-inflammatory activity of free and encapsulated <i>A. malaccensis</i> leaf extract in RAW 264.7 cells	297
7.1	Viability percentage of all concentrations of ALEX-M, ALEX-M-PNCs and B-PNCs tested on zebrafish embryo	305
7.2	Statistical analysis on embryo spontaneous movement at 24 hpf	307
7.3	The percentage of NO production in zebrafish embryos upon treatment with tested samples	319

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
1.1	<i>Aquilaria</i> leaves	3
1.2	Halal elements embodied in the research scope	9
1.3	Thesis Outline	11
2.1	Chemical structures of anti-inflammatory compounds isolated from <i>Aquilaria</i> species	59
2.2	(a) <i>A. malaccensis</i> tree trunk (b) <i>A. malaccensis</i> leaves and flowers	65
2.3	Illustration of different types of nanocarriers	72
3.1	Research Flowchart	92
3.2	Fractionation process of <i>A. malaccensis</i> leaves extract	101
3.3	Schematic diagram presenting ALEX-M-PNCs preparation by w/o/w emulsion technique	110
4.1	GC-MS chromatogram of <i>A. malaccensis</i> ethanolic leaf extract.	122
4.2	FTIR spectrum of <i>A. malaccensis</i> ethanolic leaf extract	124
4.3	LC-Q-TOF-MS Total Ion Chromatogram (TIC) of the ethanolic extract of <i>A. malaccensis</i> leaf on the negative ion mode (a) and positive ion mode (b)	126
4.4	(a) benzoic acid backbone structure, (b) cinnamic acid backbone structure	127
4.5	Fragmentation of benzophenones	128
4.6	Structures of major flavonoid backbones	132
4.7	Xanthone backbone structure	140
4.8	Sterols backbone structure	141
4.9	Isoprene unit structure	142
4.10	Fragmentation of coumarins	143
4.11	Structure of Lignan	144
4.12	Tocopherols structure	146
4.13	Percentage of protein denaturation inhibition by <i>A. malaccensis</i> leaf extract	153
4.14	Anti-lipoxygenase activity of <i>A. malaccensis</i> leaf extract	154
4.15	Level of NO produced by LPS-activated RAW264.7 macrophages	156
5.1	The scheme of the chromatographic isolation of compounds from dichloromethane fraction	163
5.2	Structure of DCM-C1 (Epifriedelanol)	164
5.3	UV spectrum of compound DCM-C1	165
5.4	HRESIMS spectrum of compound DCM-C1	165
5.5	IR spectrum of compound DCM-C1	166
5.6	¹ H-NMR spectrum of compound DCM-C1	171
5.7	¹³ C-NMR spectrum of compound DCM-C1	172
5.8	¹ H- ¹ H COSY spectrum of compound DCM-C1	173

5.9	Structure of DCM-C2 (5-Hydroxy-7,4'-dimethoxyflavone)	174
5.10	UV spectrum of compound DCM-C2	175
5.11	HRESIMS spectrum of compound DCM-C2	175
5.12	IR spectrum of compound DCM-C2	176
5.13	¹ H-NMR spectrum of compound DCM-C2 (CDCl ₃ , 500Hz)	182
5.14	¹³ C-NMR spectrum of compound DCM-C2 (CDCl ₃ , 125Hz)	183
5.15	¹ H- ¹ H COSY spectrum of compound DCM-C2 (CDCl ₃ , 500Hz)	184
5.16	HMQC spectrum of compound DCM-C2	185
5.17	HMBC spectrum of compound DCM-C2	186
5.18	Structure of DCM-C3 (Luteolin-7,3',4'-trimethyl ether)	187
5.19	UV spectrum of compound DCM-C3	188
5.20	HRESIMS spectrum of compound DCM-C3	188
5.21	IR spectrum of compound DCM-C3	189
5.22	The ¹ H-NMR spectrum of DCM-C3	194
5.23	The ¹³ C-NMR spectrum of DCM-C3	195
5.24	The ¹ H- ¹ H COSY spectrum of compound DCM-C3	196
5.25	The HMQC spectrum of compound DCM-C3	197
5.26	The HMBC spectrum of compound DCM-C3	198
5.27	Structure of DCM-C4 (5,3'-dihydroxy-7,4'-dimethoxyflavone or Luteolin 7,4'-dimethyl ether)	199
5.28	UV spectrum of compound DCM-C4	200
5.29	HRESIMS spectrum of compound DCM-C4	200
5.30	IR spectrum of compound DCM-C4	201
5.31	The ¹ H-NMR spectrum of DCM-C4	206
5.32	The ¹³ C-NMR spectrum of DCM-C4	207
5.33	The ¹ H- ¹ H COSY spectrum of DCM-C4	208
5.34	The HMQC spectrum of DCM-C4	209
5.35	The HMBC spectrum of DCM-C4	210
5.36	The scheme of the chromatographic isolation of compounds from ethyl acetate fraction	212
5.37	The structure of EA-C5 (5,7-dihydroxy-4'-methoxyflavone or Acacetin)	213
5.38	UV spectrum of compound EA-C5	214
5.39	HRESIMS spectrum of compound EA-C5	214
5.40	IR spectrum of compound EA-C5	215
5.41	The ¹ H-NMR spectrum of compound EA-C5	220
5.42	The ¹³ C-NMR spectrum of compound EA-C5	221
5.43	The ¹ H- ¹ H COSY spectrum of compound EA-C5	222
5.44	The HMQC spectrum of compound EA-C5	223
5.45	The HMBC spectrum of compound EA-C5	224
5.46	The structure of EA-C6 (Aquilarinenside E)	225
5.47	UV spectrum of compound EA-C6	226
5.48	HRESIMS spectrum of compound EA-C6	226
5.49	IR spectrum of compound EA-C6	227

5.50	The ¹ H-NMR spectrum of compound EA-C6	231
5.51	The ¹³ C-NMR spectrum of compound EA-C6	232
5.52	The ¹ H- ¹ H COSY spectrum of EA-C6	233
5.53	The structure of EA-C7 (Iriflophenone 2-O- α -L-rhamnopyranoside)	234
5.54	UV spectrum of EA-C7	235
5.55	HRESIMS spectrum of EA-C7	235
5.56	IR spectrum of EA-C7	236
5.57	The ¹ H-NMR spectrum of EA-C7	241
5.58	The ¹³ C-NMR spectrum of EA-C7	242
5.59	The ¹ H- ¹ H COSY spectrum of EA-C7	243
5.60	The structure of EA-C8 (Iriflophenone 3-C- β -glucoside)	244
5.61	UV spectrum of EA-C8	245
5.62	HRESIMS spectrum of EA-C8	245
5.63	IR spectrum of EA-C8	246
5.64	The ¹ H-NMR spectrum of EA-C8	251
5.65	The ¹³ C-NMR spectrum of EA-C8	252
5.66	The ¹ H- ¹ H COSY spectrum of EA-C8	253
5.67	The HMQC spectrum of EA-C8	254
5.68	The HMBC spectrum of EA-C8	255
5.69	Effect of the crude extract on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	258
5.70	Effect of DCM-C1 on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	259
5.71	Effect of DCM-C2 on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells	260
5.72	Effect of DCM-C3 on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	261
5.73	Effect of DCM-C4 on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	262
5.74	Effect of EA-C5 on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	263
5.75	Effect of EA-C6 on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	263
5.76	Effect EA-C7 on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	264
5.77	Effect of the crude extract on (a) NO levels and (b) % of NO inhibition, in LPS/IFN γ -induced NO production in RAW 264.7 cells.	265
6.1	The calibration curve of ALEX-M in (a) deionized water (b) PBS PH 7.4	275

6.2	Particle size distribution by intensity of ALEX-M-PNCs measured by DLS technique	276
6.3	Zeta Potential of ALEX-M-PNCs measured by DLS technique	278
6.4	TEM images of ALEX-M-PNCs at different magnifications	279
6.5	In-vitro release of ALEX-M from ALEX-M-PNCs in 48 hours	283
6.6	Thermogravimetry diagram of ALEX-M, ALEX-M-PNCs and B-PNCs	285
6.7	FTIR spectra of (a) ALEX-M, (b) B-PNCs and (c) ALEX-M-PNCs	287
6.8	Concentration dependent cytotoxicity effect of LPS/INF γ , ALEX-M, ALEX-M-PNCs, B-PNCs and Ibuprofen against RAW 264.7 cell line.	289
6.9	NaNO $_2$ standard curve used to obtain NO concentration	292
6.10	Effect of ALEX-M, ALEX-M-PNCs and B-PNCs on LPS induced NO in RAW 264.7 cells	296
7.1	(a) Stages of development of zebrafish embryos (QR code) (b) Synchronized embryos at 4-5 hpf under inverted microscope	301
7.2	Signs of toxicity in zebrafish embryos: egg development at 6hpf (a), normal embryo showing no signs of toxicity at 24 hpf (b), QR Code (spontaneous movement of zebrafish embryo and heart beats in zebrafish larvae) (c), coagulation (d), non- detachment of tail (e), lack of somite formation (f), death of larva (g)	302
7.3	Dose response to viability of zebrafish embryos at 96 hpf, exposed to ALEX-M (6.25-800 μ g/mL) and ALEX-M-PNCs and B-PNCs at concentrations (6.25-100 μ g/mL)	306
7.4	Spontaneous movement of zebrafish embryos at 24 hpf, exposed to ALEX-M (6.25-800 μ g/mL) and ALEX-M-PNCs and B-PNCs at concentrations (6.25-50 μ g/mL)	308
7.5	Malformations in zebrafish larva: normal larva at 72 hpf (a), spinal curvature (b), scoliosis (c), pericardial edema (d)	309
7.6	Effect of different concentrations of the tested samples on hatchability percentage in zebrafish embryo.	311
7.7	Effect of different concentrations of the tested samples on the heart rate in zebrafish embryo.	313
7.8	Dose response of embryonic zebrafish mortality at 96 hpf, exposed to ALEX-M (6.25 - 100 μ g/mL) and ALEX-M-PNCs and B-PNCs at concentrations (0.625 – 2.5 μ g/mL)	315
7.9	Quantitative analysis of fluorescence intensity of zebrafish embryos after staining with DAF-FM-DA using imageJ program.	319
7.10	Fluorescence micrographs of LPS-stimulated NO generation in zebrafish embryos showing the effect of	320

ALEX, ALEX-M-PNCs and B-PNCs on LPS-induced NO production.



LIST OF EQUATIONS

<u>Equation No.</u>		<u>Page</u>
3.1	$\text{Yield \% (wt/wt)} = \frac{W1}{W2} * 100$	95
3.2	$\text{Cell viability \%} = \frac{\text{Viable cells}}{\text{Total cells}} * 100$	100
3.3	$\text{Cell viability \%} = \left[\frac{(\text{Abs. of Treatment} - \text{Abs. of Blank})}{(\text{Abs. of Control} - \text{Abs. of Blank})} \right] * 100$	105
3.4	$\text{Cell viability} = \frac{\text{O. D Treated Cells} - \text{O. D Blank}}{\text{O. D Untreated Cells} - \text{O. D Blank}} * 100$	106
3.5	$\begin{aligned} &\text{\% of inhibition of protein denaturation} \\ &= \frac{\text{O. D control} - \text{O. D test}}{\text{O. D control}} * 100 \end{aligned}$	107
3.6	$\begin{aligned} &\text{\% of inhibition of lipoxygenase activity} \\ &= \frac{(\text{O. D control} - \text{O. D blank}) - (\text{O. D test} - \text{O. D Blank})}{(\text{O. D control} - \text{O. D blank})} * 100 \end{aligned}$	108
3.7	$\begin{aligned} &\text{NO Inhibition (\%)} \\ &= \left[\frac{\text{O. D LPS Treated Cells} - \text{O. D Test}}{\text{O. D LPS Treated Cells}} \right] * 100 \end{aligned}$	109
3.8	$\begin{aligned} &\text{Encapsulation Efficiency (EE)\%} \\ &= \left[\frac{\text{Total extract} - \text{Free extract}}{\text{Total extract}} \right] * 100 \end{aligned}$	112
3.9	$\begin{aligned} &\text{Loading Capacity (LC)\%} \\ &= \left[\frac{\text{Weight of Encapsulated Extract}}{\text{Weight of nanocapsules}} \right] * 100 \end{aligned}$	112
3.10	$\begin{aligned} &\text{Release \%} \\ &= \frac{\text{Amount of extract released from nanocapsules}}{\text{Amount of extract initially entrapped in nanocapsules}} * 100 \end{aligned}$	113
3.11	$\text{\% of Hatchability} = \frac{\text{No. of hatched embryos}}{\text{Initial no. of embryos}}$	115
6.1	$\frac{61.122\% - LC}{1 - 26.14\% - LC} = \frac{57.072\%}{1 - 31.62\%}$	284

LIST OF ABBREVIATIONS

NSAIDs	Non-steroidal anti-inflammatory drugs
OECD	Organization for Economic Cooperation and Development
AlCl ₃	Aluminum Chloride
NO	Nitric oxide
PGE ₂	Prostaglandin E ₂
NF- κ B	Nuclear factor kappa B
TNF α	Tumor necrosis factor- α
ILs	Interleukins
PLA ₂	Phospholipase A ₂
COX	Cyclooxygenase
LOX	Lipoxygenase
PGs	Prostaglandins
TXs	Thromboxanes
LTs	Leukotrienes
BSA	Bovine Serum Albumin
iNOS	Induced nitric oxide synthase
LPS	Lipopolysaccharide
WHO	World Health Organization
FTIR	Fourier Transformed Infrared Spectroscopy
IR	Infrared
GC-MS	Gas Chromatography Mass Spectrometry
LC-MS	Liquid Chromatography Mass Spectrometry
HPLC	High Performance Liquid Chromatography
MS	Mass Spectrometry
LC	Liquid Chromatography
ESI	Electron Spray Ionization
CC	Column Chromatography
TLC	Thin layered Chromatography
UV	Ultraviolet
NMR	Nuclear Magnetic Resonance
¹ H-NMR	Proton nuclear magnetic resonance
¹³ C-NMR	Carbon-13 nuclear magnetic resonance
COSY	Correlation Spectroscopy
HMBC	Heteronuclear Multiple Bond Correlations
HMQC	Heteronuclear Multiple Quantum Coherence
GLUT4	Glucose transporter type 4
GRAS	Generally recognized As Safe
PLA	poly lactic acid
PGA	poly (D, L-glycolic acid)
PLGA	poly lactide-co-glycolide
o/w	Oil-in-water emulsion
w/o	Water-in-oil emulsion
w/o/w	Water-in-oil-water emulsion
o/w/o	Oil-in-water-in-oil emulsion

PLA-TPGS	Poly lactide Tocopheryl Polyethylene Glycol Succinate
TG	Tragacanth Gum
FDA	Food and Drug Administration
CC ₅₀	Cytotoxic Concentration that causes death of 50% of cells
DLS	Dynamic Light Scattering
PDI	Polydispersity Index
ZP	Zeta potential
EE	Encapsulation Efficiency
LC	Loading Capacity
TEM	Transmission Electron Microscope
UV-Vis	Ultraviolet Visible
TGA	Thermogravimetric Analysis
Hpf	Hours Post Fertilization
Dpf	Days Post Fertilization
DMSO	Dimethyl Sulfoxide
ROS	Reactive Oxygen Species
LC ₅₀	Lethal concentration that causes death to 50% of the test subjects
KAED	Kulliyah of Architecture and Environmental Design
DMEM	Dulbecco's Modified Eagle's Medium
FRIM	Forest Research Institute Malaysia
WST-1	4-[3-(4iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
BUE	British university in Egypt
DAF-FM-DA	4-Amino-5-methylamino-2',7'-difluorofluorescein diacetate
OEC	Oral Epithelial Cells
CREAM	Central Research and Animal Facility
UPM	Universiti Putra Malaysia
rpm	Rotation per minute
TIC	Total Ion Chromatography
NIST	National Institute of Standards and Technology
LC-Q-TOF-MS	Liquid Chromatography Quadrupole Time of Flight Mass Spectrometry
HRESIMS	High-Resolution Electrospray Ionization Mass Spectrometry
CCHE	Cancer Children Hospital Egypt
MP-WS	Mobile Phase Working Solution
PCDL	Personal Compound Databases and Library
MoNA	MassBank of North America
HMDB	Human Metabolome Database
FBS	Fetal Bovine serum
PBS	Phospahe Buffer Saline
VLC	Vaccum Liquid Chromatography
IFN- γ	Interferon- γ
IC ₅₀	Inhibitory concentration that causes inhibition of the effect by 50%
EC ₅₀	Effective concentration that gives 50% of maximum response
Kcps	Kilo count per second
ALEX-M	Aquilaria Leaf Extract obtained by Macceration

ALEX-M-PNCs	Aquilaria Leaf Extract obtained by Macceration Polymeric Nanocapsules
B-PNCs	Blank nanocapsules
ZFET	Zebrafish Embryo Toxicity Test
LC ₅₀	Lethal concentration that causes death to 50% of the test subjects
bpm	beat per minute
SD	Standard Deviation
ANOVA	Analysis of Variance
RT	Retention Time
SFE	Supercritical Fluid Extraction
NDGA	Nordihydroguaiaretic Acid
HRF	Heterocyclic Ring Fission
BFF	Benzofuran Ring Fission
RDA	Retro-Diels Alder
HPETEs	Hydro peroxy eicosa tetraenoic acids
ppm	Part per minute
Rf	Retention factor
DCM	Dichloromethane
EA	Ethyl Acetate
UPSI	Universiti Pendidikan Sultan Idris
DCM-C1	Dichloromethane-compound 1
DCM-C2	Dichloromethane-compound 2
DCM-C3	Dichloromethane-compound 3
DCM-C4	Dichloromethane-compound 4
EA-C5	Ethyl acetate-compound 5
EA-C6	Ethyl acetate-compound 6
EA-C7	Ethyl acetate-compound 7
EA-C8	Ethyl acetate-compound 8
HLB	Hydrophilic Lipophilic Balance
FESEM	Field Emission Scanning Electron Microscope